We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Asterand Signs Agreement with Eisai Co.
News

Asterand Signs Agreement with Eisai Co.

Asterand Signs Agreement with Eisai Co.
News

Asterand Signs Agreement with Eisai Co.

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Asterand Signs Agreement with Eisai Co."

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Asterand plc announces that its subsidiary BioSeek, LLC has signed a two-year collaboration agreement with Eisai Co., Ltd., a research-based human health care company headquartered in Japan.

Under the agreement, BioSeek will apply its proprietary BioMAP® platform to advance Eisai’s multiple discovery projects in the oncology and inflammation areas. The agreement encompasses scientific projects at Eisai sites in the U.S. and Japan. The financial terms include research funding, success milestones payments and license fees: specific terms were not disclosed.

Asterand CEO, Martyn Coombs commented: “We are honoured that Eisai has chosen to incorporate BioSeek’s unique BioMAP® technology platform into its drug discovery process. This master agreement is yet another strong endorsement of our BioMAP® human-based disease model. We look forward to assisting Eisai in its quest to develop new therapies for cancer and inflammatory conditions.”

BioMAP® Systems are primary cell-based models of human disease biology, designed to replicate the intricate cell and pathway interactions as they are observed in human pharmacology and toxicology. Depending on their mechanism of action, drug compounds induce specific patterns of changes in these systems (BioMAP® profiles) that can be compared to a large number of reference profiles in the BioMAP® Database.

BioMAP® provides early insight into human pharmacological and toxicological properties of compounds, including on- and off-target effects, dose responses, and the discrimination of closely related compounds.
Advertisement